Chimerix, Inc. (CMRX): Price and Financial Metrics


Chimerix, Inc. (CMRX): $2.25

-0.10 (-4.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CMRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CMRX POWR Grades

  • Value is the dimension where CMRX ranks best; there it ranks ahead of 92.71% of US stocks.
  • The strongest trend for CMRX is in Growth, which has been heading up over the past 179 days.
  • CMRX ranks lowest in Stability; there it ranks in the 4th percentile.

CMRX Stock Summary

  • CMRX's current price/earnings ratio is 1.25, which is higher than merely 0.78% of US stocks with positive earnings.
  • With a year-over-year growth in debt of -88.09%, CHIMERIX INC's debt growth rate surpasses just 1.62% of about US stocks.
  • As for revenue growth, note that CMRX's revenue has grown 982.74% over the past 12 months; that beats the revenue growth of 98.92% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHIMERIX INC are ATRA, ARCT, BOLT, RGNX, and VIR.
  • Visit CMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.chimerix.com.

CMRX Valuation Summary

  • CMRX's price/sales ratio is 5.9; this is 195% higher than that of the median Healthcare stock.
  • Over the past 117 months, CMRX's EV/EBIT ratio has gone up 118.1.

Below are key valuation metrics over time for CMRX.

Stock Date P/S P/B P/E EV/EBIT
CMRX 2022-11-25 5.9 0.7 1.3 -0.5
CMRX 2022-11-23 6.0 0.7 1.3 -0.5
CMRX 2022-11-22 5.9 0.7 1.3 -0.5
CMRX 2022-11-21 5.9 0.7 1.3 -0.5
CMRX 2022-11-18 5.9 0.7 1.3 -0.5
CMRX 2022-11-17 5.9 0.7 1.3 -0.5

CMRX Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -10.11%.
  • The year over year cash and equivalents growth rate now stands at -0.38%.
  • Its 2 year net cashflow from operations growth rate is now at -21.65%.
Over the past 33 months, CMRX's revenue has gone up $20,537,000.

The table below shows CMRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 33.056 -60.902 153.629
2022-06-30 0.608 -83.318 -106.293
2022-03-31 0.559 -85.481 -100.588
2021-12-31 1.979 -99.93 -173.236
2021-09-30 3.053 -74.952 -145.413
2021-06-30 4.555 -67.963 -138.264

CMRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CMRX has a Quality Grade of C, ranking ahead of 50.17% of graded US stocks.
  • CMRX's asset turnover comes in at 0.038 -- ranking 340th of 682 Pharmaceutical Products stocks.
  • CDXC, NAII, and PLX are the stocks whose asset turnover ratios are most correlated with CMRX.

The table below shows CMRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.038 1 -1.745
2021-03-31 0.051 1 -2.103
2020-12-31 0.055 1 -0.855
2020-09-30 0.104 1 -0.533
2020-06-30 0.100 1 -1.270
2020-03-31 0.088 1 -1.075

CMRX Price Target

For more insight on analysts targets of CMRX, see our CMRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.67 Average Broker Recommendation 1.33 (Strong Buy)

CMRX Stock Price Chart Interactive Chart >

Price chart for CMRX

CMRX Price/Volume Stats

Current price $2.25 52-week high $7.42
Prev. close $2.35 52-week low $1.27
Day low $2.24 Volume 897,500
Day high $2.30 Avg. volume 2,746,562
50-day MA $1.94 Dividend yield N/A
200-day MA $2.94 Market Cap 198.10M

Chimerix, Inc. (CMRX) Company Bio


Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need. The company was founded in 2000 and is based in Durham, North Carolina.


CMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CMRX Latest Social Stream


Loading social stream, please wait...

View Full CMRX Social Stream

Latest CMRX News From Around the Web

Below are the latest news stories about CHIMERIX INC that investors may wish to consider to help them evaluate CMRX as an investment opportunity.

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | November 29, 2022

Chimerix Responds to Rubric Capital Management

Highlights Confidence in Ongoing Strategy and Future Clinical Development PlansDURHAM, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, issued the following statement regarding a press release issued today by Rubric Capital Management: At Chimerix, we focus on oncology therapies most likely to have profound impact on patients and crea

Yahoo | November 10, 2022

Rubric Capital Management Sends Letter to Chimerix Board of Directors

NEW YORK, November 10, 2022--Rubric Capital Management LP ("Rubric"), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. ("Chimerix" or the "Company") (NASDAQ: CMRX), today sent a letter to Chimerix’s Board of Directors (the "Board").

Yahoo | November 10, 2022

Zacks.com featured highlights Chimerix, Vista Oil & Gas and Arcus Biosciences

Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.

Yahoo | November 7, 2022

Durham drugmaker eyes potential roadmap to profitability after $238M deal

A Durham biopharmaceutical company has established a new therapeutic focus after closing the sale of its sole commercial product.

Yahoo | November 4, 2022

Read More 'CMRX' Stories Here

CMRX Price Returns

1-mo 24.31%
3-mo 1.35%
6-mo 26.40%
1-year -60.18%
3-year -11.07%
5-year -49.10%
YTD -65.01%
2021 33.13%
2020 137.93%
2019 -21.01%
2018 -44.49%
2017 0.65%

Continue Researching CMRX

Here are a few links from around the web to help you further your research on Chimerix Inc's stock as an investment opportunity:

Chimerix Inc (CMRX) Stock Price | Nasdaq
Chimerix Inc (CMRX) Stock Quote, History and News - Yahoo Finance
Chimerix Inc (CMRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9007 seconds.